Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 14 1 2025 01 01 The efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renoprotection in lupus nephritis: a comprehensive review e12724 e12724 10.34172/npj.2025.12724 EN Shankar Prasad Nagaraju https://orcid.org/0000-0003-1016-8280 Shilna Muttickal Swaminathan https://orcid.org/0000-0002-1189-157X Priya Rani https://orcid.org/0000-0002-6202-5700 Indu Ramachandra Rao https://orcid.org/0000-0001-5061-739X Ravindra Prabhu Attur https://orcid.org/0000-0002-5980-7197 Dharshan Rangaswamy https://orcid.org/0000-0002-6152-7493 Srinivas Vinayak Shenoy https://orcid.org/0000-0001-7405-4106 Ankur Gupta https://orcid.org/0000-0003-1390-3914 Mohan V Bhojaraja https://orcid.org/0000-0002-1814-2360 Journal Article 10.34172/npj.2025.12724 2024 07 25 2024 11 10 Lupus nephritis (LN) is a major organ condition in systemic lupus erythematosus (SLE) leading to end-stage kidney disease if not managed effectively. Two main therapeutic approaches that are successful in the management of LN include immunosuppression and non-immunosuppressive drugs, renin-angiotensin-aldosterone system inhibitors, and hydroxychloroquine (HCQ), which are supported by numerous clinical trials. Recent clinical trials with sodium-glucose cotransporter-2 inhibitors (SGLT2i) have consistently shown substantial evidence of reno-protection for those with IgA nephropathy and focal segmental glomerulosclerosis. However, emerging evidence shows the protective role of SGLT2i in renal outcomes for the management of LN. This review explores the underlying mechanisms by which SGLT2i contributes to nephroprotection, with promising evidence from both animal and human studies, and guideline recommendations regarding its utilization in LN.